72

Bioinformatics of the Brain

[135] R. Mejzini, L. L. Flynn, I. L. Pitout, et al., “Als genetics, mecha-

nisms, and therapeutics: Where are we now?,” Frontiers in Neuro-

science, vol. 13, 12 2019.

[136] S. Najafi, P. Najafi, N. K. Farkhad, et al., “Mesenchymal stem cell ther-

apy in amyotrophic lateral sclerosis (als) patients: A comprehensive re-

view of disease information and future perspectives,” Iranian journal of

basic medical sciences, vol. 26, pp. 872–881, 2023.

[137] B. J. Wainger, E. Kiskinis, C. Mellin, et al., “Intrinsic membrane hyper-

excitability of amyotrophic lateral sclerosis patient-derived motor neu-

rons,” Cell Reports, vol. 7, pp. 1–11, 4 2014.

[138] K. Fujimori, M. Ishikawa, A. Otomo, et al., “Modeling sporadic als

in ipsc-derived motor neurons identifies a potential therapeutic agent,”

Nature Medicine, vol. 24, pp. 1579–1589, 10 2018.

[139] S. Morimoto, S. Takahashi, D. Ito, et al., “Phase 1/2a clinical trial in

als with ropinirole, a drug candidate identified by ipsc drug discovery,”

Cell Stem Cell, vol. 30, pp. 766–780.e9, 6 2023.

[140] K. Imamura, Y. Izumi, A. Watanabe, et al., “The src/c-abl pathway is

a potential therapeutic target in amyotrophic lateral sclerosis,” Science

Translational Medicine, vol. 9, 5 2017.

[141] K. Imamura, Y. Izumi, M. Nagai, et al., “Safety and tolerability

of bosutinib in patients with amyotrophic lateral sclerosis (idream

study): A multicentre, open-label, dose-escalation phase 1 trial,” eClin-

icalMedicine, vol. 53, p. 101707, 11 2022.

[142] S. Thams, E. R. Lowry, M.-H. Larraufie, et al., “A stem cell-based

screening platform identifies compounds that desensitize motor neurons

to endoplasmic reticulum stress,” Molecular Therapy, vol. 27, pp. 87–

101, 1 2019.

[143] N. J. Lamas, B. Johnson-Kerner, L. Roybon, et al., “Neurotrophic re-

quirements of human motor neurons defined using amplified and purified

stem cell-derived cultures,” PLoS ONE, vol. 9, p. e110324, 10 2014.

[144] E. Abati, N. Bresolin, G. Comi, et al., “Advances, challenges, and per-

spectives in translational stem cell therapy for amyotrophic lateral scle-

rosis,” Molecular Neurobiology, vol. 56, pp. 6703–6715, 10 2019.

[145] A. Aljabri, A. Halawani, G. B. Lajdam, et al., “The safety and efficacy

of stem cell therapy as an emerging therapy for als: A systematic review

of controlled clinical trials,” Frontiers in Neurology, vol. 12, 12 2021.